Aurobindo Pharma share news, announcements and annual reports
NSE: AUROPHARMABSE: 524804Pharmaceuticals & BiotechnologyMid Cap
Aurobindo Pharma Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 1995 on BSE, Jul 2000 on NSE
Last close ₹1,681.40up ₹21.50 (1.30%)BSE ₹1,677.80
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,659.90.
30 Oct: open ₹1,652.00, high ₹1,687.00, low ₹1,647.20
52-week range of traded prices to 30 Oct 2026
₹1,091.20Low, 30 Oct 2025₹1,740.00High, 24 Sep 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results and dividend. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹96,744 Cr138th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 26.06
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.55
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 10.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 11.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.20
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 9,52,65057.5% delivered
Aurobindo Pharma share news and announcements
1,689 announcements, routine notices left out, newest first. Page 27 of 34.
Jul 2012
Jun 2012
19 Jun · Disclosure
Compensation Committee of Directors of the Company on June 19, 2012, has considered and approved grant of 3,00,000 options at an exercise price of Rs.106.05 per option (each option confer a right to one equity share of Re.1/- each) under the Employees Stock Option Plan, 2006.
May 2012
30 May · Board meeting
30 May · Meeting
Annual General Meeting of the Company will be held on August 07, 2012. Further the Register of Members and Share Transfer Books of the Company will be closed from August 01, 2012 to August 07, 2012 (both days inclusive) for the purpose of Annual General Meeting and for payment of dividend for the year 2011-12.30 May · Dividend
Board of Directors of the Company at its meeting held on May 29, 2012, has recommended final dividend @ 100% on the equity share capital of the Company i.e. Re. 1/- per share subject to approval of Shareholders.9 May · Board meeting
Inter alia, to consider and approve the Audited Financial Results of the Company for the financial year ended March 31, 2012.
Apr 2012
Mar 2012
Feb 2012
14 Feb · Business
10 Feb · Board meeting
Company had informed the Exchange that a meeting of the Board of Directors of the Company will be held on February 10, 2012 to consider inter alia, the Un-Audited Financial Results of the Company for the quarter ended December 31, 2011. The Company has now informed the Exchange that aforesaid Board Meeting has been postponed due to unavoidable circumstances. The meeting is now scheduled to be held on February 13, 2012.
Jan 2012
30 Jan · Board meeting
To consider inter alia, the Un-Audited Financial Results of the Company for the quarter ended December 31, 2011.